An open-label, parallel-group, repeat-dose study to investigate the effects of end stage renal disease and haemodialysis on the pharmacokinetics of ropinirole (study RRL103628).

Trial Profile

An open-label, parallel-group, repeat-dose study to investigate the effects of end stage renal disease and haemodialysis on the pharmacokinetics of ropinirole (study RRL103628).

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Parkinson's disease; Restless legs syndrome
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Mar 2006 to Apr 2006 as reported by Clinicaltrials.gov.
    • 12 Oct 2008 Trial phase changed from II to I as reported by ClinicalTrials.gov.
    • 09 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top